CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group Limited has announced that its new Class I bi-functional fusion protein drug, JMT108, has received approval from China’s National Medical Products Administration to commence clinical trials. This drug, designed to enhance anti-tumor efficacy by targeting PD-1 positive tumor infiltrating immune cells, shows promise for treating advanced malignant tumors, having demonstrated significant anti-tumor effects and a good safety profile in preclinical studies.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated company operating in the pharmaceutical industry. It focuses on developing innovative drugs, with a particular emphasis on bi-functional fusion protein drugs for cancer treatment.
YTD Price Performance: 3.05%
Average Trading Volume: 4,196
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.95B
For an in-depth examination of 1093 stock, go to TipRanks’ Stock Analysis page.